Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB122 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BIIB122 225 mg | EXPERIMENTAL | Oral 225 mg dose, once daily (QD) |
| BIIB122 Matching Placebo | PLACEBO_COMPARATOR | Oral BIIB122 matching placebo, once daily (QD) |
| Name | Type | Description |
|---|---|---|
| BIIB122 225 mg | DRUG | Administered as specified in the treatment arm |
| BIIB122-Matching Placebo | OTHER | Administered as specified in the treatment arm |
Inclusion Criteria: * For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years * For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years * Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant. * Have a clinical diagnosis of PD meeting the Mov...
Top 12 of 20 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Eli Lilly and Company | LLY | 3 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| AgeX Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
BIIB122 is an investigational small molecule being studied for the treatment of Parkinson Disease, specifically in participants with LRRK2-associated Parkinson's disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
BIIB122 targets LRRK2, a protein kinase implicated in the pathogenesis of Parkinson's disease. By inhibiting LRRK2, the drug aims to address a genetic and biological pathway associated with the disease, though its efficacy and safety are still being evaluated in clinical trials.
BIIB122 is being developed by Denali Therapeutics Inc., a biopharmaceutical company focused on neurodegenerative diseases. Denali Therapeutics is publicly traded under the ticker symbol DNLI on the NASDAQ stock exchange.
BIIB122 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is assessing its safety and pharmacodynamic effects in participants with LRRK2-associated Parkinson's disease.
BIIB122 is being evaluated in a Phase 2 clinical trial with the identifier NCT06602193. This randomized, double-blind, placebo-controlled study is investigating the safety and pharmacodynamic effects of BIIB122 in participants with LRRK2-associated Parkinson's disease. The trial is active but not recruiting, with an enrollment of 50 participants across the United States, Germany, Israel, and Spain.